Treating the Dream Enactment Is the Easy Part. Telling Him What It Might Mean Is Not.
The medication decision here is close to routine. What the team actually argues about is a harder question the diagnosis itself raises — one that has nothing to do with the prescription pad.
W.H., a 62-year-old man, retired two years ago after a long career as a structural engineer and has spent much of his retirement restoring an old sailboat with his son, a project he talks about at length and clearly enjoys. He was referred to a sleep clinic after his wife described, with real and growing alarm, several months of him punching and kicking during sleep — once catching her in the shoulder hard enough to leave a bruise she still points to when she talks about it. He has no memory of any of these episodes afterward, but he does recall vivid, often violent dreams occurring around the same nights — being chased through unfamiliar streets, fighting off an attacker in the dark — that roughly match the physical movements his wife describes.
He is otherwise healthy: no psychiatric history of any kind, well-controlled hypertension on a single daily medication he has taken without issue for years, and, on direct questioning, no tremor, no change in his handwriting that he or his wife has noticed, no loss of his sense of smell, and no concerns about his memory or thinking from either of them. He walks two miles most mornings with a neighbor and has had no falls or balance problems.
A polysomnogram confirmed REM sleep without atonia and behaviors consistent with REM sleep behavior disorder, with no other sleep pathology — no obstructive sleep apnea, no periodic limb movements — identified as an alternative explanation for the movements. His wife’s immediate question in clinic was about her own physical safety and his; his own question, asked more quietly once the diagnosis was actually explained, was different — he had, on his own, searched the diagnosis online before the appointment, found its documented association with Parkinson’s disease, and wants to know, directly and without being talked around, what that might mean for him.
In clinic, after the polysomnogram confirmed the diagnosis
The treatment decision is genuinely straightforward. Clonazepam, typically 0.5–1 mg at bedtime, has been the first-line agent for RBD dream-enactment behavior for decades of clinical practice, and given his wife’s bruising, treating for injury prevention isn’t optional — it’s the immediate priority regardless of anything else in this conversation.
What I don’t think we should do is answer his Parkinson’s question with reassurance that isn’t warranted. He asked directly, having already researched it himself; deflecting or minimizing at this point would likely just push him to search further alone, without a clinician to contextualize what he finds.
I agree on both counts, and I’d be specific about the actual numbers rather than either alarming him or softening them. Postuma and colleagues’ large multicenter prospective study of isolated RBD found an overall conversion rate to Parkinson’s disease or a related synucleinopathy of roughly 6.3% per year, with cumulative risk reaching about 73.5% at twelve years — real and substantial, but not a diagnosis of Parkinson’s itself, and not something with a defined timeline for any individual patient.
His clean neurologic exam today — no tremor, no bradykinesia, intact sense of smell by his own report — is genuinely reassuring information in that same framework, since several of the strongest predictors of nearer-term conversion (abnormal motor exam, olfactory deficit) aren’t present. I’d tell him honestly that the association is real and significant, that his current exam doesn’t show the features most associated with sooner conversion, and that periodic neurologic follow-up, not panic, is the right response.
The one thing I’d add is about pacing, not content. He came in today for his wife’s bruised shoulder, and in the span of one visit he’s also being told about a real, unfixable, disease-linked risk with no timeline. I don’t think that means withholding anything — he asked, and I agree he deserves a real answer — but I’d want this framed as the start of an ongoing conversation with neurology, not everything he needs to absorb today, and I’d make sure he leaves with a concrete follow-up plan, not just information.
Agreed: clonazepam started for symptom control and injury prevention, bedroom safety measures discussed, and an honest, specific conversation about the RBD-synucleinopathy association had directly with W.H., grounded in real conversion-rate data rather than vague reassurance or alarm.
A neurology referral for baseline exam and periodic monitoring was placed the same day, framed explicitly as the start of an ongoing relationship rather than a single disclosure visit.
All three voices converged on treating both the acute safety problem and the longer-term prognostic conversation as equally real obligations of this visit — the only genuine tension was pacing, resolved by scheduling a concrete neurology follow-up rather than by saying less today.